Shri Krishna Devcon Limited (SHRIKRISH) fundamentals

Shri Krishna Devcon Limited is a listed company in Realty, part of the Realty sector, listed on the NSE as SHRIKRISH (ISIN INE997I01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What Shri Krishna Devcon Limited does

Shri Krishna Devcon Limited is an India-based company, which is engaged in real estate development and construction of properties. The Company is primarily involved in the business of construction, development of townships, housing projects, commercial premises and other related activities. The Company is developing projects mainly in Indore (Madhya Pradesh) and Mumbai (Maharashtra). Its projects include Shrikrishna Corridor, Shri Krishna Enclave, Shri Krishna Emerald Greens, Shri Krishna Emerald Greens II, Shrikrishna Premium Corridor, Shri Krishna Residence, Shri Krishna Divine Greens, Shri Krishna Leela Greens, Shri Krishna Enclave Premium, and Avani Signature. Its subsidiary is Shrikrishna Buildcon.

Valuation and market data

Last close₹37.00
Market capitalisation₹103 crore
Enterprise value₹117 crore
P/E (TTM)0.00
Price to book1.19
Price to sales (TTM)4.96
Book value per share₹30.97
Dividend yield0.00%
SectorRealty
IndustryRealty
Listed sinceMon Apr 20

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹22 crore₹6 crore₹5 crore0.00
Mar 2025₹27 crore₹7 crore₹5 crore1.76
Mar 2024₹26 crore₹6 crore₹4 crore1.59
Mar 2023₹32 crore₹7 crore₹5 crore1.72
Mar 2022₹21 crore₹4 crore₹3 crore0.99

Figures are as reported (standalone), in ₹ crore.

Shareholding pattern

As of Jun 2026:

Promoters54.9%
Foreign institutions (FII)0.0%
Mutual funds0.0%
Other domestic institutions0.0%
Retail and others45.1%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.